Integra’s MicroMatrix Flex Study Reaches Completion, Setting Up Next Steps for IART Investors

Integra Lifesciences (IART) announced an update on their ongoing clinical study.

Integra LifeSciences (IART) is running a completed prospective study called “Prospective Evaluation of MicroMatrix® Flex in Wounds Complicated by Tunneling and Undermining.” It aims to see how well MicroMatrix Flex works and how safe it is in difficult wounds such as pressure injuries, venous ulcers, and diabetic ulcers that have tunnels or undermining.

The study tests three Integra wound care devices used together. These are MicroMatrix Flex, MicroMatrix UBM Particulate, and Cytal Wound Matrix 2-Layer, all designed to support healing in complex, hard-to-treat wounds and used one time on each wound.

This is an interventional study with one treatment group and no comparison arm. All enrolled patients receive the same device combination, and there is no masking, which means doctors and patients know which treatment is given, with the main goal focused on treatment outcomes rather than comparison.

The trial is listed as completed, with Integra as the sponsor, and the most recent update posted on March 3, 2026. While the exact first treatment and completion dates are not disclosed here, the updated status suggests that follow-up is done and the company is now moving closer to analyzing and, potentially, sharing results.

For investors, the key point is that this study supports Integra’s advanced wound care portfolio, which targets a growing market in chronic and complex wounds. Positive data could strengthen IART’s position versus other wound care players, improve confidence in the product line, and modestly support sentiment on the stock as hospitals seek reliable options for complex wound management.

The study has been completed and recently updated, and more detailed information is available on the ClinicalTrials portal.